NAD+ was first discovered in the early 1900s and is a metabolite of vitamin B or B3 specifically. It was used primarily orally then injected intramuscularly. It was not until the 1960s that is was purified into NAD+ and used clinically on patients in formal published peer reviewed clinical trials via intravenous application.

A pioneer in the use of NAD+ was Dr. Birkmeyer. He invented the L-dopa protocol, which he used in Parkinson’s patients to help with mobility. His son, George Birkmeyer, later discovered that with NAD+ supplementation they could achieve better clinical responses and help more patients.

Fast forward to today, NAD+ boosting strategies have emerged as promising clinical interventions for a variety of neurological conditions including dementia, Alzheimer’s, brain fog, memory issues, mild and traumatic brain injury. In fact, cognitive improvement is the most commonly reported benefit by patients who undergo NAD+ therapy.

Research still continues into this area with new papers being published every week on the clinical application of NAD+ for neurological disorders. While results are promising, it is important to be aware that more large-scale clinical research in humans is still needed to fully elucidate mechanisms of action and therapeutic efficacy for neurological disorders.